ALK7-Binding Proteins for Metabolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for overweight, obesity, and type 2 diabetes are inadequate, as they often result in modest weight loss and do not effectively address the underlying metabolic disorders associated with ALK7 signaling.
Innovation Solution
ALK7-binding proteins are developed to inhibit ALK7 binding with its ligands and receptors, thereby blocking signaling pathways that contribute to obesity, metabolic syndrome, and type 2 diabetes, using specific antibodies that bind to ALK7 with high affinity and specificity, reducing body weight and improving metabolic parameters.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Weight of moving object
If current treatments for overweight and obesity are used, then weight loss is achieved, but the weight loss is modest and does not effectively address underlying metabolic disorders
Solution Approach 1:
The patent introduces ALK7-binding proteins as intermediary molecules that mediate between the ALK7 receptor and its ligands. These proteins block the interaction between ALK7 and its ligands (such as GDF1, GDF3, GDF8, activin A/B, and Nodal), thereby inhibiting the signaling pathway that promotes obesity and metabolic disorders. This intermediary approach allows for more effective targeting of the underlying metabolic pathology rather than merely suppressing weight gain.
Solution Approach 2:
The patent changes the molecular parameter of the ALK7 signaling pathway by introducing binding proteins that alter the binding affinity and interaction dynamics between ALK7 and its ligands. This parameter change results in the inhibition of downstream signaling events that are critical for obesity and type 2 diabetes pathogenesis, leading to more substantial and sustained weight loss and metabolic improvement compared to current treatments.
2Reliability
If ALK7 binding is inhibited, then metabolic disorders are improved, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent extracts the critical interaction between ALK7 and its ligands by introducing specific binding proteins that isolate and block this interaction. The binding proteins are designed to specifically target the ALK7-ligand interface, separating this critical pathway from the rest of the complex signaling network. This extraction approach simplifies the treatment mechanism by focusing on a specific, manageable interaction rather than attempting to modulate the entire ALK7 signaling pathway simultaneously.
Solution Approach 2:
The ALK7-binding proteins serve as intermediary molecules that simplify the treatment mechanism by providing a direct and specific block to the ALK7-ligand interaction. These intermediaries are designed to be relatively simple in structure and function, making the overall treatment mechanism more manageable despite the complexity of the underlying metabolic disorders. The intermediaries can be administered as monoclonal antibodies or antibody fragments, which are well-established therapeutic modalities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ALK7-binding proteins effectively reduce body weight, improve metabolic disorders, and ameliorate conditions such as insulin resistance, fatty liver disease, and cardiovascular diseases by inhibiting ALK7-mediated signaling, offering a more substantial and sustained impact than existing treatments.
Implementation Method 1
the ALK7-binding proteins are capable of inhibiting or blocking the binding of ALK7 to one or more cognate ALK7 ligands and/or one or more cognate ActRII receptors
Data Source
AI summary
This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented, or ameliorated by targeting ALK7.